



SEMPERIT GROUP Q1-3 2021 INVESTOR PRESENTATION

Petra Preining, CFO

Kristian Brok, COO

17 November 2021



Agenda

Key Highlights (p.2)

Operational Performance (p.6)

Financial Performance (p.14)

Strategy and Outlook (p.22)

Appendix (p.25)



Q3 2021 Highlights, Strategy and Outlook



Record results achieved in Q1-3'2021 – despite considerable raw materials and logistics headwinds



Industrial Sector: strong order book recovery and performance against the backdrop of supply chain headwinds – converging towards strong 2019 pre-corona level



Proactive working capital management resulted in working capital as % of LTM revenues improving versus 2019 and 2020



Pursuing the previously announced strategy with full focus on implementation and disciplined execution, with strong support from Supervisory Board



Momentum of high price environment for protective gloves of Q2'21 begins to wane in Q3'21 - price decline accelerates into Q4'21




**Update of outlook from March 2021:
EBITDA slightly lower than original target of roughly € 395m for FY 2021 due to raw materials, logistics and labour headwinds**





Excellent results against exogenous price pressure


- Performance of Medical Sector still on record level despite declining ASPs
- Industrial Sector: recovering top-line growth against margin



- **Record top-line at Q1-3'21**
 - Medical Sector at € 517m, up by +79% yoy
 - Industrial Sector at € 409m, up by +11% yoy
- **EBITDA at € 324m with strong operating margin**
 - Medical Sector still benefits from high price environment (€ 277m) despite deterioration of price levels
 - Industrial Sector: recovery impacted by difficult supply chain conditions (€ 65m)
- **EBIT at € 290m**
 - Clearly above last year despite one-off effects in Q1-3'20
- **Focus remains on inorganic and organic growth**



Major drivers of strong operating performance





Agenda

Key Highlights (p.2)

Operational Performance (p.6)

Financial Performance (p.14)


Strategy and Outlook (p.22)

Appendix (p.25)




Resilient Industrial Sector: recovering top-line growth against margin pressure

Revenues Q1-3'19 – Q1-3'21



Quarterly development of EBITDA 2019-2021



- While revenues increased by 11% yoy, EBITDA gap reduced to only -1% vs. Q1-3'20; headwinds from heavily increasing raw materials and logistics prices offset by price adjustments though with a time lag
- Industrial segments very resilient due to the restructuring programme of the past years






Industrial Sector: strong raw materials headwinds

- **Significantly higher materials costs and logistics constraints remain challenging**
- **Strong operational efficiency supports margin development: EBITDA margin if adjusted for raw materials and purchased services' price increases would have been significantly higher (approx. +6PP)**

Price indices Butadiene
(as main raw material for
synthetic rubber / latex)

Price index LFO-F-NWE

Price index wire rod




¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2020 = 100.0




Semperflex Q1-3 2021

Strong recovery after Covid

Semperflex



Q1-3 2021 vs. Q1-3 2020



- Revenue significantly up yoy as growth recovery gains momentum
- Strong operating performance despite raw materials' availability and cost, energy cost and supply chain disruptions and costs
- Close monitoring of cost drivers and prices required
- Continuously growing order book







Sempertrans Q1-3 2021

Late cyclicality and price pressure impact the business

Sempertrans



Q1-3 2021 vs. Q1-3 2020



- Improved order book with first signs of market recovery
- Positive operational results against considerably low utilisation and negative volume effects
- Ongoing price pressure for raw materials, energy and logistics – with challenges in the project business due to limited scope for price adjustments
- Segment continues to receive highest management attention



1) Q1'19 EBITDA: positive effects of € 1.3m profit from sale of assets of closed factory in China,



2) Q3'21 EBITDA: positive effect of € 3.7m from recycling of foreign exchange differences




Sempersal Q1-3 2021

Strong top-line and margin growth

Sempersal



Q1-3 2021 vs. Q1-3 2020



- Order book well above comparable period in 2020 supporting further market share gains
- Strong demand in machinery, electronics and chemicals results in significant top-line growth
- Continued high pressure of raw materials' costs impact EBITDA and EBIT
- Price increases implemented due to rising input costs supporting margin development







Semperform Q1-3 2021

Continuing top-line growth despite margin pressure

Semperform



Q1-3 2021 vs. Q1-3 2020



- Strong order intake results in growing order book exceeding Q1-3'20 level
- Top-line growth at handrail and SES exceeding comparable period in 2020, especially in railway, piping and household industries
- Notable price inflation from raw materials and logistics but also lower share of high-margin businesses (ski tourism) impact margins






Medical Sector / Sempermed segment Q1-3 2021

Price development passed its peak but still above pre-Corona levels – results at record levels

Sempermed



Q1-3 2021 vs. Q1-3 2020

Revenue current period	517
Revenue comparable period	288
EBITDA current period	277
EBITDA comparable period	67

in € m

- Price plateau at end of Q1'21 and prices slightly weakening in Q2'21 followed by a stronger decline in Q3'21 and significant decrease in Q4'21
- Operating cash flow impacted by inventory build-up due to limited container availability
- Sales volumes in Q3'21 under pressure due to EMCO, however, offset by prices being still at above pre-Corona levels



1) Q3'19 EBITDA adjusted for € 4m due to release of provision in Sempermed for Brazilian court case for tax liabilities



Agenda

Key Highlights (p.2)

Operational Performance (p.6)


Financial Performance (p.14)

Strategy and Outlook (p.22)

Appendix (p.25)



Revenue development




% change of each segment / sector refers to H1 2021 vs. H1 2020.



Top-line growth translates into higher reported EBITDA

Medical Sector strong - Industrial Sector resilient

in € m



Q1-3 2020 Semperflex Sempertrans Semperséal Semperform Sempermed Corporate **Q1-3 2021**

EBITDA
Q1-3 2020

118.5

34.8

8.7

9.4

12.4

67.3

-14.1

EBITDA
Q1-3 2021

37.4

6.5

10.7

9.9

277.4

-17.7

324.3

EBITDA margin
Q1-3 2021

21.7%

8.2%

11.7%

14.9%

53.7%

–

35.0%



Overview of key financial KPIs, Q1-3'19 – Q1-3'21

	Q1-3'19	Q1-3'20	Q1-3'21
EBITDA, in € m	60.4	118.5	324.3
EBITDA margin, in %	9.3	18.0	35.0
EBIT, in € m	-13.7	159.5	290.0
EBIT margin, in %	-2.1	24.3	31.3
Earnings after tax, in € m	-34.1	137.3	224.1
Free Cashflow, in € m	60.2	98.8	160.1
CAPEX, in € m	25.1	17.4	31.2




Quarterly CAPEX development 2020-2021

- CAPEX increased against its low level in 2020
- Industry starts to invest in growth CAPEX
- Outlook 2021: planned to be well above the low level in 2020

CAPEX per segment


in € m





Free cash flow development

- Further improved results but headwinds from raw materials and logistics
- Operating CF driven by strong performance but also impacted by working capital requirements
- Investment CF includes USD time deposits (€ 48m)
- Free CF (adjusted for investments in USD time deposits) more than doubled




¹⁾ Q1-3 2021 free cash flow adjusted for investments in USD time deposits (€ -48m) included in investment cash flow (in total € -80m)



Working Capital overview

Components of Working Capital

in € m




¹⁾ Trade Working Capital in % of LTM revenues



Balance sheet structure and financial profile

Balance sheet structure

Balance sheet 30/09/2021: € 974m
Balance sheet 31/12/2020: € 764m



Financial profile as of 30 September 2021

- **Cash, cash equivalents (238) and USD time deposit (48) totalling € 286m**
- **Unused credit facilities total € 90m**
- **Corporate Schuldschein loan at € 170m – paid in November 2021 € ~84m**
- **Net debt turns to net cash (including USD time deposits) at € 113m, Net debt / EBITDA below zero (YE'20: 0.1x)**
- **Equity ratio of 51.7% (YE'20: 43.5%)**



Agenda

Key Highlights (p.2)

Operational Performance (p.5)

Financial Performance (p.13)

Strategy and Outlook (p.22)

Appendix (p.25)



Outlook and focus on disciplined strategy execution

- **Update of outlook from March 2021:
Despite raw materials, logistics and labour headwinds
EBITDA only slightly lower than original target of roughly € 395m for FY 2021**
- **Momentum of high price environment for protective gloves of Q2'21 begins to wane in Q3'21 - price decline accelerates into Q4'21**
- **Focus on strategic growth of Semperit's Industrial Sector**
- **Pursuing the previously announced strategy with full focus on implementation and disciplined execution, with strong support from Supervisory Board**



Contact and financial calendar

Investor Relations Semperit

Judit Helenyi, Director Investor Relations

+43 1 79777 - 310

www.semperitgroup.com/en/ir

Modecenterstrasse 22

1031 Vienna, Austria

Financial Calendar 2021

17.11.2021	Report on Q1-3 2021
23.3.2022	Publication of 2021 annual financial statements
27.4.2022	Annual general meeting, Vienna
18.5.2022	Report on Q1 2022
17.8.2022	Half-year financial report 2022
16.11.2022	Report on Q1-3 2022

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



Agenda

Key Highlights (p.2)

Operational Performance (p.5)

Financial Performance (p.13)

Strategy and Outlook (p.22)

Appendix (p.25)



Sectors and Group: Q1-3 2021 vs Q1-3 2020

	Industrial Sector			Medical Sector			Semperit Group		
in EUR m	Q1-3 2021	Q1-3 2020	%	Q1-3 2021	Q1-3 2020	%	Q1-3 2021	Q1-3 2020	%
Revenue	409.4	369.0	+11.0%	516.7	288.2	79.3%	926.1	657.2	+40.9%
EBITDA	64.5	65.3	-1.2%	277.4	67.3	>100%	324.3	118.5	>100%
EBITDA margin	15.8%	17.7%	-1.9 PP	53.7%	23.4%	+30.3 PP	35.0%	18.0%	+17.0 PP
EBIT	46.0	26.9	+70.9%	262.6	147.5	78.1%	290.0	159.5	+81.9%
EBIT margin	11.2%	7.3%	+3.9 PP	50.8%	51.2%	-0.3 PP	31.3%	24.3%	+7.1 PP
Adj. EBIT	46.0	46.8	-1.7%	262.6	60.7	>100%	290.0	92.6	>100%
Adj. EBIT margin	11.2%	12.7%	-1.4 PP	50.8%	21.1%	+29.8 PP	31.3%	14.1%	+17.2 PP
Earnings after tax	-	-	-	-	-	-	224.1	137.3	+63.2%
Adj. Earnings after tax	-	-	-	-	-	-	224.1	62.6	+0.0%
Earnings per share in EUR	-	-	-	-	-	-	10.8	6.4	+70.1%
Adj. Earnings per share in EUR	-	-	-	-	-	-	10.8	0.99	-90.9%
Additions in tangible and intangible assets									
Employees	3,720	3,474	+7.1%	3,170	3,311	-4.3%	7,027	6,921	+1.5%

Figures of Semperit Group also contain intercompany consolidation and the results of the Corporate Segment




Semperit Group adj. where applicable


Semperit Group adj. where applicable

in EUR m	FY 2018	Q1 2019	Q2 2019	Q3 2019 adj. ¹⁾	Q4 2019 adj. ²⁾	FY 2019	Q1 2020	Q2 2020 adj. ³⁾	Q3 2020 adj. ⁴⁾	Q4 2020 adj.	FY 2020 adj. ⁵⁾	Q1 2021	Q2 2021	Q3 2021
Revenue	878.5	212.9	224.4	214.9	188.3	840.6	199.1	219.8	238.2	270.5	927.6	323.1	337.7	265.3
EBITDA	50.3	16.5	22.7	17.3	7.4	63.8	16.9	40.7	60.9	90.0	208.6	122.2	125.3	76.8
EBITDA margin	5.7%	7.7%	10.1%	8.0%	3.9%	7.6%	8.5%	18.5%	25.6%	33.3%	22.5%	37.8%	37.1%	28.9%
EBIT	15.4	7.8	13.1	8.1	-0.7	28.2	9.8	33.6	49.2	78.8	171.4	110.8	113.8	65.4
EBIT margin	1.7%	3.7%	5.8%	3.8%	-0.4%	3.4%	4.9%	15.3%	20.7%	29.1%	18.5%	34.3%	33.7%	24.7%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Q3 2019 adjusted for negative one-off effect of € 47m from impairment of Sempermed (adj. for EBIT) and € 4m (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities. ²⁾ Q4 2019: impairment figure of Q3 2019 stepped up by € 2m due to additions to assets and FY deviations ³⁾ Q2 2020: adjusted for the positive one-off effect from the write-up in the Sempermed segment (EBIT: EUR 88.8 million) and the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect –20.0 Million EUR) ⁴⁾ Q3 2020: adjusted for the special effect from the write-up in the Sempermed segment (EBIT: EUR –2.1 million) and the special effect from the impairment in the Sempertrans segment (EBIT effect EUR +0.1 million). ⁵⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR –19.8 million)



Semperflex and Sempertrans (adj. where applicable)

Semperflex (Hoses)													
	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021
in EUR m													
Revenue	61.1	59.7	53.8	48.0	222.7	46.8	51.5	46.6	45.0	189.9	54.7	59.7	57.7
EBITDA	13.9	14.5	10.8	8.7	47.9	9.3	14.0	11.4	7.2	41.9	12.3	13.9	11.2
EBITDA margin	22.8%	24.3%	20.1%	18.1%	21.5%	19.9%	27.2%	24.5%	16.0%	22.1%	22.5%	23.3%	19.3%
EBIT	11.1	11.5	7.7	5.7	36.0	6.5	11.2	8.7	4.5	30.9	9.6	11.1	8.4
EBIT margin	18.2%	19.2%	14.3%	11.9%	16.2%	13.9%	21.8%	18.6%	10.0%	16.3%	17.5%	18.5%	14.5%

Sempertrans (Conveyor belts)													
	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020 adj. ¹⁾	Q3 2020 adj. ²⁾	Q4 2020 ³⁾	FY 2020 adj. ⁴⁾	Q1 2021	Q2 2021	Q3 2021
in EUR m													
Revenue	30.4	37.8	35.1	30.6	134.0	29.5	32.5	28.4	22.7	113.1	26.9	24.2	28.0
EBITDA	2.7	5.4	4.6	0.8	13.5	1.6	5.0	2.1	0.0	8.7	1.0	0.8	4.7
EBITDA margin	9.0%	14.2%	13.1%	2.5%	10.1%	5.4%	15.4%	7.6%	0.0%	7.7%	3.8%	3.3%	16.7%
EBIT	1.8	3.8	3.6	-0.3	8.9	0.6	3.9	1.4	-0.6	4.9	0.2	-0.1	3.8
EBIT margin	6.0%	10.0%	10.4%	-0.9%	6.7%	1.9%	11.9%	5.0%	-2.6%	4.3%	0.7%	-0.2%	13.6%

¹⁾ Q2 2020: adjusted for the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect: EUR 20.0 million).

²⁾ Q3 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

³⁾ Q4 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

⁴⁾ 2020: Adjusted for the negative one-off effect of the impairment in the Sempertrans segment (2020 EBIT effect: EUR 19.8 million)



Semperform and Semperseal (adj. where applicable)

Semperform (Window and door profiles, Handrails) - before 2020

	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019
in EUR m						
Revenue	192.2	49.9	50.5	47.8	42.4	190.6
EBITDA	21.9	7.9	8.3	6.6	3.3	26.0
EBITDA margin	11.4%	15.7%	16.4%	13.8%	7.8%	13.6%
EBIT	13.2	5.4	5.9	4.2	0.5	16.0
EBIT margin	6.9%	10.9%	11.6%	8.7%	1.1%	8.4%

Semperform (Window and door profiles, Handrails) - starting 2020, 2019 pro forma split

	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021
in EUR m													
Revenue	22.4	24.6	22.3	21.8	91.1	19.9	21.9	20.4	19.6	81.8	19.8	23.6	23.3
EBITDA	4.0	4.8	4.1	2.7	15.6	3.5	5.0	4.0	2.5	15.0	3.1	3.6	3.3
EBITDA margin	17.7%	19.6%	18.4%	12.2%	17.1%	17.5%	22.6%	19.6%	12.9%	18.3%	15.4%	15.2%	14.1%
EBIT	3.1	4.0	3.2	1.7	12.0	2.6	4.1	3.1	1.6	11.3	2.1	2.6	2.3
EBIT margin	13.9%	16.1%	14.3%	7.7%	13.1%	12.9%	18.5%	15.1%	8.0%	13.8%	10.8%	11.2%	10.0%

Sempersal (Profiles and Rubber Sheeting) - starting 2020, 2019 pro forma split

	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021
in EUR m													
Revenue	27.5	25.8	25.6	20.5	99.5	25.4	21.7	24.4	22.2	93.6	28.7	30.3	32.4
EBITDA	3.9	3.4	2.5	0.6	10.4	3.3	3.2	2.9	1.7	11.0	4.2	2.4	4.1
EBITDA margin	14.1%	13.2%	9.8%	3.0%	10.5%	12.8%	14.7%	12.0%	7.5%	11.8%	14.7%	7.9%	12.6%
EBIT	2.3	1.9	1.0	-1.2	4.0	1.8	1.7	1.4	0.2	5.1	2.6	0.8	2.5
EBIT margin	8.4%	7.3%	3.9%	-5.8%	4.0%	6.9%	8.0%	5.8%	1.1%	5.5%	9.2%	2.6%	7.7%

Split of former Semperform into Sempersal and Semperform as of 1st January 2020 – historic Semperform numbers for 2019 adapted for this split accordingly



Sempermed (adj. where applicable)

Sempermed (Gloves)													
	Q1 2019	Q2 2019	Q3 2019 adj. ¹⁾	Q4 2019	FY 2019 ²⁾	Q1 2020	Q2 2020 adj. ³⁾	Q3 2020 adj. ⁴⁾	Q4 2020 ⁵⁾	FY 2020 adj. ⁶⁾	Q1 2021	Q2 2021	Q3 2021
in EUR m													
Revenue	71.5	76.4	78.2	67.3	293.3	77.5	92.2	118.4	161.1	449.2	192.9	199.8	124.0
EBITDA	-0.9	0.6	1.8	-0.1	1.4	4.8	18.2	44.4	83.0	150.4	105.3	115.3	56.9
EBITDA margin	-1.2%	0.8%	2.3%	-0.1%	0.5%	6.1%	19.7%	37.5%	51.5%	33.5%	54.6%	57.7%	45.9%
EBIT	-2.8	-1.4	-0.3	-0.9	-5.5	4.4	17.6	38.9	77.8	138.7	100.2	110.3	52.1
EBIT margin	-3.9%	-1.9%	-0.4%	-1.4%	-1.9%	5.5%	19.1%	32.8%	48.3%	30.9%	52.0%	55.2%	42.0%

¹⁾ Q3 2019 adjusted for negative one-off effect of EUR 46.8 million from impairment of Sempermed (adj. for EBIT) and EUR 4 million (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities.

²⁾ 2019: adjusted for the positive one-off effect from the reversal of a provision for the tax procedure on levies in Brazil (EBITDA, EBIT: EUR 4.0 million), as well as the negative effect of the impairments for the Sempermed segment (EBIT: -48.8 million EUR)

³⁾ Q2 2020: adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT: EUR +88.8 million)

⁴⁾ Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -2.1 million)

⁵⁾ Q4 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -0.5 million)

⁶⁾ 2020: adjusted for the positive one-off effect of the reversal of impairment in the Sempermed segment (2020 EBIT effect: EUR +86.2 million)



Key figures 2010-2020

Key performance figures											
in EUR m	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ⁴⁾	2015 ⁴⁾	2016 adj. ⁴⁾	2017 adj. ⁴⁾	2018 adj. ⁵⁾	2019 adj. ⁶⁾	2020 adj. ⁷⁾
Revenue	689.4	820.0	828.6	906.3	858.3	914.7	852.4	874.2	878.5	840.6	927.6
EBITDA	112.3	110.0	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8	208.6
EBITDA margin	16.3%	13.4%	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%	22.5%
EBIT	82.3	80.4	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2	171.4
EBIT margin	11.9%	9.8%	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.4%	18.5%
Earnings after tax	45.4	51.8	46.2	54.9	37.8	46.4	15.2	-43.9	-17.3	-0.2	121.9
Gross cash flow	91.0	89.4	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.70	193.7
Return on equity	12.9%	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%	58.0%


Balance sheet key figures											
in EUR m	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ⁴⁾	2015 ⁴⁾	2016	2017	2018	2019	2020
Balance sheet total	593.5	616.7	824.5	852.1	826.3	937.8	1034.5	853.2	768.8	701.8	764.4
Equity	351.1	379.4	406.2	411.5	443.8	363.3	329.3	278.5	329.5	273.4	332.3
Equity ratio	59.2%	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%	43.5%
Investments in tangible and intangible assets (CAPEX)	52.5	45.1	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.9	26.4
Employees, at balance sheet date, FTEs	7,019	8,025	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902	6,943

¹⁾ 2011 restated (see Annual Report 2012, Notes 2.18), 2010 not restated. ²⁾ 2014 and 2015 restated. ³⁾ 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. ⁴⁾ 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from impairment at Sempermed (€ 26m adj. EBIT, EAT only), from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ⁵⁾ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only). ⁶⁾ FY 2019 adjusted for positive one-off effects of € 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of € 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). ⁷⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR; earnings after tax effect: +88.8 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million; earnings after taxes effect: EUR -16.1 million)



Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable





¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Overview price indices LFO-F-NWE / wire rod

Significant increase for raw material¹⁾ used in industrial segments



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Product / market position / segment overview, FY 2020

in EUR m

Semperit Group

Group	Industrial Sector				Medical Sector	
	Semperflex	Sempertrans	Semperform ⁴⁾	Semperseal ⁴⁾	Sempermed	
Revenue	927.6	189.9 / 20% ¹⁾	113.1 / 12% ¹⁾	81.8 / 9% ¹⁾	93.6 / 10% ¹⁾	449.2 / 48% ¹⁾
EBITDA	208.6 ²⁾	41.9	8.7	15.0	11.0	150.4
Employees	6,943 ²⁾	1,571 / 23% ³⁾	917 / 13% ³⁾	520 / 7% ³⁾	457 / 7% ³⁾	3,337 / 48% ³⁾

Products and market position

Hydraulic hoses

3 position globally / leader in hose only



Industrial hoses

2 - 3 position in Europe



Conveyor belts

One of the leading providers for heavy-duty steel and textile cord belts



HSA* / SES**

Leading European manufacturers of moulded and extrusion products made of rubber and plastics (handrails, cable car rings, ski foils and Engineered Solutions)



Profiles / Rubber Sheeting

Leading European manufacturer of sealing profiles and elastomer sheeting (construction, packaging, machinery, HVAC, marine, electric systems)



Examination gloves

Among the top 15 glovemakers in the world



Surgical gloves

Among the leading companies in Europe



*Handrails, Special Applications
** Semperit Engineered Solutions

¹⁾ Revenue in % of Group revenue.

²⁾ Group figure includes corporate center of € -18m, 136 employees.

³⁾ Employees in % of Group employees.


⁴⁾ The business units Profiles and Rubber

Sheeting were separated from the Semperform segment and are operated as individual segments under the name Semperseal as of 1 January 2020.



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C